Zhongxin client April 8 (Shangguanyun) On the 8th, Cao Xuejun, deputy director of the Consumer Products Industry Department of the Ministry of Industry and Information Technology, introduced at the press conference that all 14 Chinese patent medicines included in the "Diagnosis and Treatment Program" were timely Monitoring, such as Lianhua Qingwen, Jinhua Qinggan and other key varieties, the enterprise has been producing at full capacity, the inventory is relatively sufficient, and the market supply is guaranteed. Up to now, the daily production capacity of Lianhua Qingwen Capsules has reached 2 million boxes and 30 million boxes in stock, and the daily production capacity of Jinhua Qinggan has reached 26,000 boxes and 400,000 boxes in stock.